[go: up one dir, main page]

ATE348152T1 - Verfahren zum screening von diabetes- heilverfahren - Google Patents

Verfahren zum screening von diabetes- heilverfahren

Info

Publication number
ATE348152T1
ATE348152T1 AT01998193T AT01998193T ATE348152T1 AT E348152 T1 ATE348152 T1 AT E348152T1 AT 01998193 T AT01998193 T AT 01998193T AT 01998193 T AT01998193 T AT 01998193T AT E348152 T1 ATE348152 T1 AT E348152T1
Authority
AT
Austria
Prior art keywords
screening diabetes
cure
diabetes cure
screening
cell
Prior art date
Application number
AT01998193T
Other languages
English (en)
Inventor
Takahide Ohishi
Jun Takasaki
Mitsuyuki Matsumoto
Chou-Ku
Tetsu Saito
Masazumi Kamohara
Takatoshi Soga
Shigeru Yoshida
Yoshitaka Ueda
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26605096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE348152(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE348152T1 publication Critical patent/ATE348152T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01998193T 2000-12-01 2001-11-30 Verfahren zum screening von diabetes- heilverfahren ATE348152T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367349 2000-12-01
JP2001243841 2001-08-10

Publications (1)

Publication Number Publication Date
ATE348152T1 true ATE348152T1 (de) 2007-01-15

Family

ID=26605096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998193T ATE348152T1 (de) 2000-12-01 2001-11-30 Verfahren zum screening von diabetes- heilverfahren

Country Status (8)

Country Link
US (3) US20030180813A1 (de)
EP (2) EP1770159A1 (de)
JP (1) JP3438186B2 (de)
AT (1) ATE348152T1 (de)
AU (1) AU2002218509A1 (de)
DE (1) DE60125227T2 (de)
ES (1) ES2280435T3 (de)
WO (1) WO2002044362A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816492B2 (en) 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030125539A1 (en) * 1999-02-22 2003-07-03 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP2002130117A (ja) * 2000-10-18 2002-05-09 Mikuni Corp 電磁駆動型プランジャポンプ
WO2002044362A1 (en) * 2000-12-01 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for diabetes
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
CA2489405A1 (en) * 2002-09-11 2004-03-25 Yamanouchi Pharmaceutical Co., Ltd. Screening method of agents for increasing insulin content
PT1599468E (pt) 2003-01-14 2008-01-14 Arena Pharm Inc Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
WO2004084944A1 (ja) * 2003-03-25 2004-10-07 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005009469A1 (ja) * 2003-07-28 2005-02-03 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DK1971862T3 (da) 2006-04-11 2011-02-14 Arena Pharm Inc Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CN101754961A (zh) * 2007-04-20 2010-06-23 先灵公司 嘧啶酮衍生物及其使用方法
US20100190687A1 (en) * 2007-04-20 2010-07-29 Boyle Craig D Pyrimidinone derivatives and methods of use thereof
JP2010526145A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
WO2008137436A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
JP5301539B2 (ja) 2007-07-17 2013-09-25 ブリストル−マイヤーズ スクイブ カンパニー Ｇｐｒ１１９ｇタンパク質共役受容体の調節方法および選択された化合物
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010009195A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
AU2009270984A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and methods of use thereof
CA2747809A1 (en) 2008-12-23 2010-07-01 Joel M. Harris Bicyclic heterocycle derivatives and methods of use thereof
WO2010075269A1 (en) 2008-12-23 2010-07-01 Schering Corporation Pyrimidine derivatives as gpcr modttlators for use in the treatment of obesity and diabetes
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
EP2504010A4 (de) 2009-11-23 2013-04-17 Merck Sharp & Dohme Fusionierte bizyklische pyrimidinderivate und verwendungsverfahren dafür
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
BR112012025590A2 (pt) 2010-04-08 2016-06-21 Bristol Myers Squibb Co análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
CA2798610A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2012115640A1 (en) * 2011-02-23 2012-08-30 Elona Biotechnologies Liquid insulin- containing compositions and methods of making the same
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2718279B1 (de) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Neue verbindungen als gpr119 modulatoren
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CA2961550A1 (en) * 2014-09-24 2016-03-31 University Of Oregon Proteins increasing pancreatic beta cell number and methods of use
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE610853A (de) 1960-12-05
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
IT1256191B (it) * 1992-12-03 1995-11-29 Impiego di lisolecitine nel trattamento della impotenza maschile e dell'alopecia e relative composizioni atte a tale impiego.
IL142153A0 (en) 1998-10-13 2002-03-10 Arena Pharm Inc Non-endogenous, constitutively activated human g protein-coupled receptors
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
EP1133559B1 (de) 1998-11-20 2005-08-10 Arena Pharmaceuticals, Inc. Menschliche, an ein g-protein gekoppelter rezeptor rup3 ohne bekannten ligand
EP1161242A4 (de) * 1999-01-29 2004-06-30 Beyer Camille F Zusammenstellungen und methoden zur behandlung von diabetes
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
GB9923177D0 (en) * 1999-09-30 1999-12-01 Pfizer Ltd Novel polypeptide
WO2001032864A2 (en) * 1999-11-03 2001-05-10 Merck Patent Gmbh Gpcr-kd5 polypeptides and dna sequences thereof
WO2001036473A2 (en) 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Human g protein-coupled receptors
JP2004500808A (ja) 1999-12-10 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド Ｇタンパク質結合受容体
AU6744501A (en) * 2000-05-18 2001-11-26 Bayer Aktiengesellschaft Regulation of human dopamine-like g protein-coupled receptor
US20040067499A1 (en) 2000-08-04 2004-04-08 Tatsuya Haga Novel g protein-coupled receptor
WO2002044362A1 (en) 2000-12-01 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for diabetes
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
EP1364013A1 (de) 2001-02-14 2003-11-26 PHARMACIA & UPJOHN COMPANY G-protein gekoppelter rezeptor

Also Published As

Publication number Publication date
DE60125227T2 (de) 2007-09-20
US7662775B2 (en) 2010-02-16
DE60125227D1 (de) 2007-01-25
US20100144677A1 (en) 2010-06-10
AU2002218509A1 (en) 2002-06-11
JPWO2002044362A1 (ja) 2004-04-02
US20030180813A1 (en) 2003-09-25
EP1770159A1 (de) 2007-04-04
EP1338651B1 (de) 2006-12-13
EP1338651A1 (de) 2003-08-27
ES2280435T3 (es) 2007-09-16
WO2002044362A1 (en) 2002-06-06
EP1338651B9 (de) 2007-05-09
EP1338651A4 (de) 2005-04-27
US20050136484A1 (en) 2005-06-23
JP3438186B2 (ja) 2003-08-18

Similar Documents

Publication Publication Date Title
ATE348152T1 (de) Verfahren zum screening von diabetes- heilverfahren
DE59008475D1 (de) Verwendung eines schwer löslichen Salzes einer Heteropolysäure zur Bestimmung eines Analyts, entsprechendes Bestimmungsverfahren sowie hierfür geeignetes Mittel.
GB2217717B (en) Process for the production of porous membranes,the membranes produced thereby and their use as supporting matrices in test strips
PT88183A (pt) Sensor of the enzime electrode type and process for realize analysis using that sensor
DE69229174D1 (de) Verwendung von haloalkylderivaten von reportermolekülen zur analyse der metabolischen aktivität in zellen
DE60029209D1 (de) Vorrichtung und verfahren zur einbringung von substanzen in eine zelle durch elektroporation
ATE418729T1 (de) Verfahren zur charakterisierung von biomolekülen mittels resultat-gesteuerter strategie
CH399779A (fr) Indicateur et son utilisation pour doser les substances dans les liquides biologiques
DE69427255D1 (de) Herstellung von Tetrazolium-Salz-Indikatoren enthaltenden diagnostischen Teststreifen
DE3788388D1 (de) Verfahren zur Herstellung eines REFETs oder eines CHEMFETs, sowie deren Herstellung.
DE60141129D1 (de) Hochdruckamboss und optisches fenster
DE60236530D1 (de) Verfahren zur vorbehandlung von proben zur bestimmung von verzuckerten aminen, sowie verfahren zur bestimmung von verzuckerten aminen
DK0414076T3 (da) Cyclisk substituerede (quinolin-2-yl-methoxy)phenyleddikesyrederivater
AU2003302816A1 (en) Method for manufacturing tool for analysis
ATE483975T1 (de) Behälter und kits zur bestimmung von zellfunktionen und verfahren zu deren bestimmung
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
SE437303B (sv) Forfarande for on-line-metning av koncentrationen av en analyt i en behallare, samt apparat for genomforande av forfarandet
ES2089132T3 (es) Analisis de pelo.
ATE222954T1 (de) Verfahren zur herstellung von dem anaphase- fördernden komplex
CA2004068A1 (en) Hair analysis method
GB2005831A (en) Analytical device
ATE440278T1 (de) Verfahren und vorrichtung zur charakterisierung von osi-material
IS3331A7 (is) Aðferð til að nota skönnunarsmásjá og myndgreini til efnagreingingar, með því að mæla meðal sætistölu frumefna í efnafösum, sem innihalda létt frumefni.
ATE196009T1 (de) Verfahren und vorrichtung zur gewinnung und zum nachweis von immunologisch aktiven substanzen aus der gasphase
TW200617391A (en) Blood sample preparation method and sampling test sheet for liver function determination

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1338651

Country of ref document: EP